Victory Capital Management’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$38.8K Sell
42,175
-267
-0.6% -$323 ﹤0.01% 2332
2025
Q4
$54.3K Buy
42,442
+335
+0.8% +$450 ﹤0.01% 2324
2025
Q3
$54.7K Sell
42,107
-1,528
-4% -$2K ﹤0.01% 2333
2025
Q2
$52.4K Sell
43,635
-614
-1% -$681 ﹤0.01% 2377
2025
Q1
$47.8K Sell
44,249
-313
-0.7% -$439 ﹤0.01% 2370
2024
Q4
$78K Sell
44,562
-1,319
-3% -$2.46K ﹤0.01% 2354
2024
Q3
$88.5K Sell
45,881
-1,086
-2% -$2.13K ﹤0.01% 2341
2024
Q2
$83.1K Buy
46,967
+10,067
+27% +$24.6K ﹤0.01% 2319
2024
Q1
$100K Buy
36,900
+25,973
+238% +$62.7K ﹤0.01% 2305
2023
Q4
$24.1K Buy
+10,927
New +$23.3K ﹤0.01% 2497
2021
Q3
Sell
-10,159
Closed -$63K 2813
2021
Q2
$63K Sell
10,159
-257
-2% -$1.37K ﹤0.01% 2653
2021
Q1
$47K Sell
10,416
-262
-2% -$1.44K ﹤0.01% 2670
2020
Q4
$64K Buy
+10,678
New +$70.2K ﹤0.01% 2445
2020
Q2
Sell
-17,328
Closed -$44K 2902
2020
Q1
$44K Buy
+17,328
New +$56.9K ﹤0.01% 2826
2019
Q4
Sell
-14,766
Closed -$68K 2963
2019
Q3
$68K Buy
+14,766
New +$116K ﹤0.01% 2564

Other funds holding LAB

Victory Capital Management's LAB Position: Q1 2026 in Review

Victory Capital Management reduced its Standard BioTools (LAB) stake by 0.63% in Q1 2026, selling an estimated $323 and leaving 42,175 shares worth $38.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

Victory Capital Management first reported a position in LAB in Q3 2019 and has held it in 15 quarters since. The position peaked at $100K in Q1 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Victory Capital Management held 42,175 shares of Standard BioTools worth $38.8K as of Q1 2026.
  • Victory Capital Management sold 267 Standard BioTools shares in Q1 2026, an estimated $323.
  • Standard BioTools made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2332 holding.
  • Victory Capital Management first reported a position in Standard BioTools in Q3 2019 and has held it in 15 quarters since.
  • Victory Capital Management's Standard BioTools position peaked at $100K in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.